Recombinant human growth hormone was approved by the FDA in 1985 for the narrow indication of pediatric growth hormone deficiency. Within a decade, off-label prescribing for anti-aging and athletic performance had emerged as a substantial parallel market. Within two decades, the parallel market had grown larger than the on-label market by patient population and roughly comparable by revenue. The federal government, in the Anabolic Steroid Control Act amendments of 1990, took the unusual step of explicitly criminalizing the prescription of growth hormone for purposes other than the FDA-approved indications—a restriction that applies to no other prescription medication in the same form. The criminalization has not stopped the prescribing. It has reshaped how the prescribing happens, where the patients seek it, and what alternative compounds have emerged to substitute for it.
The clinical case against growth hormone use for anti-aging or general performance enhancement is reasonably well-established. The classic study published by Rudman and colleagues in NEJM in 1990, which is sometimes cited as evidence supporting growth hormone’s anti-aging applications, documented modest changes in body composition in older men receiving growth hormone supplementation. Subsequent and larger studies have confirmed the body composition effects but have not demonstrated the broader functional or longevity benefits that the anti-aging marketing of growth hormone has emphasized. The Mayo Clinic systematic review and other authoritative analyses have concluded that growth hormone administration in healthy older adults produces modest cosmetic changes at substantial cost and meaningful risk.
The risk profile of growth hormone administration is not trivial. Insulin resistance, joint pain, fluid retention, and carpal tunnel syndrome are common short-term effects. Longer-term concerns include potential effects on cancer risk, particularly in patients with predispositions, and cardiovascular effects whose magnitude in this population is not well-characterized. The clinicians who prescribe growth hormone for off-label purposes tend to acknowledge these risks while arguing that careful monitoring can manage them; the regulatory bodies that have evaluated the practice have generally concluded that the risk-benefit balance does not support routine prescribing for non-deficient patients.
What has happened in the regulatory environment over the past two decades is a quiet substitution toward growth hormone secretagogues—peptides that stimulate the patient’s own pituitary to release growth hormone rather than supplementing growth hormone directly. Sermorelin, ipamorelin, CJC-1295, and several related compounds produce some of the same metabolic effects as direct growth hormone administration but are not subject to the same statutory restrictions. The peptides are, in some cases, themselves FDA-approved for narrow indications and prescribed off-label; in other cases they are compounded preparations with no FDA approval but with regulatory pathways through the compounding framework. The wellness clinic sector that previously prescribed growth hormone has, to a significant degree, migrated toward the secretagogue alternatives.
The clinical evidence base for the secretagogue peptides is, if anything, weaker than the evidence base for growth hormone itself. The compounds were originally developed as research tools and clinical investigations for narrow indications—growth hormone deficiency assessment, treatment of cachexia in specific contexts—rather than as general therapeutic agents. The phase 2 and phase 3 development programs that would have produced robust evidence for any of the broader applications under which they are now marketed were largely abandoned, often for commercial reasons unrelated to the compounds’ therapeutic potential. The clinical use that has expanded around them is, in pharmaceutical regulatory terms, off-label use of products that are themselves at the margins of approval, often dispensed through compounding pathways whose individualization requirements are honored more in form than in substance.
There is a separate phenomenon adjacent to the wellness clinic sector that the public conversation has engaged unevenly: the use of growth hormone and related compounds in athletics. USADA’s prohibited substance list includes growth hormone, growth hormone-releasing factors, and the relevant secretagogue peptides. Athletic testing has documented sustained use of these compounds in elite athletics for decades. The amateur athletic and bodybuilding community uses them at substantially higher rates than elite sport, and the consumer market for the compounds is materially larger than the elite sport market. The regulatory framework that addresses doping in sport does not, in any meaningful way, reach the consumer market that produces most of the demand.
The wellness clinic sector’s prescribing of growth hormone secretagogues has been characterized, in the FDA’s enforcement letters and various medical board investigations, as practice that strains the boundaries of legitimate compounding and off-label prescribing. The clinics document clinical justifications—age-related decline in growth hormone levels, lab values within population norms but described as ‘suboptimal,’ symptom complexes that align loosely with growth hormone deficiency syndromes. The documentation generally suffices to establish that a prescription was issued for a particular patient with a stated clinical rationale. Whether the rationale satisfies the standard of care that medical boards expect is a question that varies by jurisdiction and by the disposition of the specific board reviewing any given case.
There is a parallel consideration that the clinical literature on aging and growth hormone has begun to engage more directly. The relationship between growth hormone and aging may, in some respects, run opposite to what the anti-aging marketing assumes. Several long-running studies of populations with reduced growth hormone signaling—patients with Laron syndrome and similar genetic conditions—have documented lower rates of cancer and diabetes than the general population. Animal studies in mice and other species have shown that reduced growth hormone signaling extends lifespan in many models. The implication, that supplementing growth hormone in older adults may, if anything, accelerate certain age-related conditions, has been entertained seriously enough in the longevity research community to give some practitioners pause about the framing of growth hormone as an anti-aging intervention.
What the growth hormone story illustrates, more starkly than perhaps any other example in this category, is the limit of regulatory restriction in shaping clinical practice when the demand is durable and the alternative substitutes are available. The 1990 statutory restrictions on growth hormone prescribing were, in formal regulatory terms, among the most aggressive responses ever applied to off-label use of an FDA-approved medication. The restrictions did not stop the prescribing. They moved some of it offshore. They moved more of it into compounded versions of the secretagogue alternatives. They moved still more of it into research peptide channels that operate outside the regulated medical framework entirely. The aggregate use of growth hormone-related compounds for non-medical purposes has, by any reasonable measure, increased rather than decreased over the four decades since the original FDA approval.
The longer-term implications of this pattern reach beyond growth hormone specifically. The wellness sector has demonstrated, repeatedly, that demand for hormonal interventions framed as anti-aging or optimization is robust enough to sustain commercial markets in the face of regulatory hostility, weak clinical evidence, and explicit professional society opposition. The patients are willing to pay. The clinicians are willing to prescribe. The supply chain is willing to produce. The regulatory framework’s various levers—criminal restrictions, off-label use limitations, compounding pathway constraints, professional licensing oversight—each address one component of the system without disabling the system as a whole. STAT analysis of longevity medicine has noted that the durability of this commercial pattern, across forty years and multiple regulatory regimes, suggests it is not a transitional phenomenon but a settled feature of the medical landscape that the regulatory framework has not figured out how to address.
What the field will probably do over the next decade, given the trajectory of the past four, is continue some form of selective enforcement against the most egregious operators while permitting the broader sector to expand. The compounds will evolve—newer secretagogue peptides, novel small molecules with growth hormone-like effects, eventually perhaps gene therapies that modulate the relevant signaling pathways. The clinical claims will adapt to whatever evidence is available and whatever regulatory framework emerges. The patient population will continue to grow, drawn by aging demographics, increasing affluence in the relevant cohorts, and the persistent cultural appeal of pharmacological intervention in age-related decline. Whether any of this produces meaningful benefit for the patients receiving the treatments is a question the field has been discussing for forty years without resolution. Whether the next forty years produce different answers depends on clinical evidence that has not yet been generated and on regulatory choices that have not yet been made. The default trajectory, absent intervention, is continued growth of a market that has demonstrated remarkable durability under conditions that should, by any conventional analysis, have constrained it long ago.
